Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and in vitro biological evaluation by REEMA ABU KHALAF et al.
631
Acta Pharm. 71 (2021) 631–643 Short communication 
https://doi.org/10.2478/acph-2021-0034
Piperazine sulfonamides as DPP-IV inhibitors: 
Synthesis, induced-fit docking and in vitro biological 
evaluation
Diabetes mellitus is a chronic illness that needs persistent 
medical attention and continuous patient self-management 
to avoid acute complications. Dipeptidyl peptidase-IV 
(DPP-IV) inhibitors minimize glucagon and blood glucose 
levels by increasing the incretin levels, glucagon-like pep-
tide (GLP-1) and glucose-dependent insulinotropic poly-
peptide (GIP), leading to insulin secretion from pancreatic 
beta cells. In the present study, nine 1,4-bis(phenylsulfonyl) 
piperazine derivatives 1a-i were synthesized and identified 
using 1H NMR, 13C NMR, MS and IR spectroscopies. 
These compounds were tested in vitro and showed inhibi-
tory  activity ranging from 11.2 to 22.6 % at 100 µmol L–1 
concentration. Piperazine sulfonamide derivatives were 
found to be promising DPP-IV inhibitors, where the pres-
ence of electron-withdrawing groups such as Cl (1a-c) im-
proved the activity of the compounds more than electron-
donating groups such as CH3 (1d-f) at the same position. 
Additionally, meta-substitution is disfavored (1b, 1e, 1g). 
Induced-fit docking studies suggested that the targeted 
compounds 1a-i occupy the binding domain of DPP-IV and 
form H-bonding with the backbones of R125, E205, E206, 
F357, K554, W629, Y631, Y662 and R669.
Keywords: piperazine sulfonamide, dipeptidyl peptidase-IV 
inhibitor, diabetes mellitus, induced-fit docking
Diabetes mellitus (DM) became a rising epidemic in the last century. It is one of the 
leading causes of death worldwide (1). About 451 million people had diabetes in 2017 and 
the number is expected to become greater than 693 million by 2045 (2). Reduced insulin 
secretion, tissue resistance to insulin, or both, are considered as common factors for DM 
development (3).
Piperazine-containing compounds were found to exert different pharmacological 
 activities, including preserving memory in animal models of Alzheimer’s disease (4), 
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α-amylase inhibitory activity (5), antibacterial, antifungal activity (6), antiplasmodial ac-
tivity (7), and HIV-1 protease inhibition (8).
Dipeptidyl peptidase-IV (DPP-IV) enzyme is a plasma soluble enzyme found in the 
capillary bed of the gut mucosa. Other organs such as the kidney, intestine and liver are 
announced to have DPP-IV enzyme. It is related to the serine proteases family and exists 
as a homodimer containing 766 amino acids with Asp-His-Ser at the active site. DPP-IV 
structure has a β-propeller domain and an α/β-hydrolase domain, where the catalytic 
peptidase function takes place (9). It removes the proline and alanine from the N-terminal 
ends of glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide 
(GIP) making them biologically inactive. Some substrates with glycine, valine, serine or 
leucine can be cleaved at a slower rate, however, the enzyme is unable to cleave substrates 
with proline in position 3 (10). DPP-IV comprises hydrophobic S1 and S2 pockets (which 
contain Arg125, Ser209, Phe357, Arg358, Tyr547, Ser631, Val656, Trp659, Tyr62, Tyr666, 
Asn710, and Val711) and S3 (Asn281, Leu294, Leu340, Val341, Ala342, and Arg343) which 
is an alternative binding site and is considered to be an allosteric binding site (11). Hydro-
phobic amino acids at the N-terminal of the enzyme (Glu205, Glu206 and Tyr662) are 
thought to increase the DPP-IV substrate specificity (12).
DPP-IV inhibitors were developed as oral antidiabetic drugs that control the blood 
glucose level by prohibiting the degradation of incretin hormones GLP-1 and GIP, which 
successfully promotes insulin secretion, inhibits glucagon release and enhances glucose 
control in patients with type 2 DM (13). The major representatives of this class are sita-
gliptin, vildagliptin, saxagliptin, teneligliptin, linagliptin, and alogliptin (14–20). Sita-
gliptin is a triazolopiperazine derivative (Fig. 1) containing amino and amide moieties (15). 
It is the first gliptin to be FDA approved (October 2006) and the recommended dose is 
100 mg once a day (16).
Earlier, our research group designed and synthesized different potential DPP-IV in-
hibitors such as: N4-sulfonamido succinamic, phthalamic, acrylic and benzoyl acetic acid 
derivatives (21), acridines (22), sulfamoyl-phenyl acid esters (23), and phenanthridine ami-
des (24). This work reports the synthesis of 1,4-bis(phenylsulfonyl) piperazine derivatives 
1a-i, as potential DPP-IV inhibitors. The target compounds were developed based on the 
presence of structural features similar to those present in sitagliptin, which are the pipe-
razine ring, benzene rings and sulfonamide moiety instead of the carboxamide group. 
Furthermore, some of the prepared compounds were fluorinated.
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Piperazine, 2-chlorophenylsulfonyl chloride and 3-chlorophenylsulfonyl chloride 
were purchased from Acros (Belgium), whereas 4-chlorophenylsulfonyl chloride, 2-tosyl-
sulfonyl chloride, 3-tosylsulfonyl chloride, 4-tosylsulfonyl chloride, 3,5-difluorophenylsul-
fonyl chloride, 2,6-difluorophenylsulfonyl chloride and 4-(trifluoromethyl)phenylsulfonyl 
chloride were purchased from Sigma-Aldrich (USA). Triethylamine, acetone, and dichlo-
romethane (CH2Cl2) were purchased from Tedia (USA). Solvents were used in the experi-
ments without further purification.
Melting points were measured using the Gallenkamp melting point apparatus (Gal-
lenkamp, UK) and were uncorrected. Infrared spectra were measured using the Shimadzu 
IR Affinity-1 spectrophotometer (Shimadzu, Japan). The samples were prepared as thin 
solid films using potassium bromide discs (Acros). NMR was recorded on Bruker 500 MHz 
AvanceIII (USA). The samples were dissolved in deuterated dimethyl sulfoxide (DMSO) 
for compounds 1a-c, 1g and 1h, or in deuterated chloroform (CDCl3) for compounds 1d-f 
and 1i. Mass spectra were recorded on Bruker Apex-IV (USA).
Pre-coated TLC plates dimension 20 × 20 cm, 0.25 mm silica gel 60 with fluorescent 
indicator under 254 nm (Macherey-Nagel, Germany) were used. AFLX800TBI microplate 
fluorimeter (BioTek Instruments, Winooski, VT, USA) was used for the in vitro bioassay. 
Column chromatography on silica gel stationary phase of high-purity grade, pore size 60 
Å, 63–200 µm (70–230 mesh) (Sigma-Aldrich) was used.
Synthesis of 1,4-bis(phenylsulfonyl) piperazine derivatives 1a-i
Compounds 1a-e, 1g and 1h. – To piperazine (0.5 g, 5.8 mmol) in acetone (5 mL), 12.8 
mmol of one of the substituted phenylsulfonyl chlorides: 2-chlorophenylsulfonyl chloride, 
3-chlorophenylsulfonyl chloride, 4-chlorophenylsulfonyl chloride, 2-tosylsulfonyl chlo-
ride, 3-tosylsulfonyl chloride, 3,5-difluorophenylsulfonyl chloride or 2,6-difluorophenyl-
sulfonyl chloride, was slowly added with cooling. The solution of NaOH (0.51 g, 12.8 mmol) 
in water (5 mL) was added to the previous mixture. This resulted in an exothermic reaction 
and a precipitate was immediately formed. Once the exothermic reaction had ceased, the 
reaction mixture was heated at reflux for 1.5 h. The precipitate which formed was filtered 
and washed with abs. ethanol (2 × 10 mL) and water (2 × 10 mL). The obtained powder was 
dried in the oven to get the targeted compounds: 1,4-bis(2-chlorophenylsulfonyl) pipera-
zine (1a), 1,4-bis(3-chlorophenylsulfonyl) piperazine (1b), 1,4-bis(4-chlorophenylsulfonyl) 
piperazine (1c), 1,4-bis(2-tosylsulfonyl) piperazine (1d) (27), 1,4-bis(3-tosylsulfonyl) pipera-
zine (1e), 1,4-bis(3,5-difluorophenylsulfonyl) piperazine (1g) or 1,4-bis(2,6-difluorophenyl-
sulfonyl) piperazine (1h) (28).
Compounds 1f and 1i. – Twenty mmol of 4-tosylsulfonyl chloride or 4-(trifluoromethyl)
phenylsulfonyl chloride was dissolved in CH2Cl2 (40 mL) in an ice bath and piperazine (10 
mmol, 0.861 g) was added. Then, triethylamine (20 mmol, 2.786 mL) was added. The reac-
tion mixture was stirred at room temperature for 48 h and then extracted with HCl solu-
tion (pH = 3). The CH2Cl2 layer was dried over anhydrous Na2SO4 and filtered. The solvent 
was evaporated. After evaporation of the solvent, the residue of 1,4-bis(4-tosylsulfonyl) 
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piperazine (1f) (27) or 1,4-bis(4-(trifluoromethyl)phenylsulfonyl) piperazine (1i), was puri-
fied by column chromatography eluting with CH2Cl2. 
In vitro DPP-IV inhibition bioassay
In vitro evaluation of DPP-IV inhibitory activity of the synthesized compounds was 
carried out using a commercially available kit [BioVision DPP-IV Inhibitor Screening Kit 
(fluorometric), USA]. In BioVision’s DPP-IV inhibitor screening kit, DPP-IV cleaves a sub-
strate (H-Gly-Pro-AMC) to release a quenched fluorescent group, AMC (7-amino-4-methyl 
coumarin), (Ex/Em = 360/460 nm). In presence of a DPP-IV inhibitor, the cleavage will be 
inhibited. Sitagliptin is included as a control inhibitor.
Two milligrams of the tested inhibitor (1a-i) were dissolved in DMSO to prepare the 
stock solution (10 mmol L–1). Serial dilution of stock solution was carried out to prepare the 
final solution (400 µmol L–1), out of which 25 µL was transferred to the 96-well plate and 
diluted 4 times to afford the final concentration of 100 µmol L–1 in the well. The 25 µL of 
the tested inhibitor (or sitagliptin) was mixed well with 50 µL of the DPP-IV enzyme and 
incubated for 10 minutes at 37 °C. Then, 25 µL of the DPP-IV substrate was added, mixed 
well and incubated for 30 minutes. Blanks were prepared in the absence of the DPP-IV 
enzyme, where 50 µL of the assay buffer was used instead.
Computational research
Preparation of protein structure. – The X-ray coordinates of DPP-IV (PDB ID: 4A5S) (25) 
were adopted from the RCSB Protein Data Bank (PDB). The coordinates were prepared and 
energetically minimized using the protein preparation (26) module in the Schrödinger 
enterprise to maximize H-bond interactions.
Preparation of ligand structures. – Structures of synthesized compounds (ligands) were 
modeled on the template of co-crystalized ligand (N7F) in 4A5S. The ligands were built 
using MAESTRO (26) build algorithm and subjected to energy minimization by Macro-
Model wizard employing the OPLS2005 force field.
Induced-fit docking (IFD). – The co-crystallized ligand N7F was identified as a centroid 
in the 4A5S binding domain. The van der Waals scaling factors for receptor and ligand 
were adjusted to 0.5 to permit enough flexibility for the best-docked ligand pose. Other 
parameters were calibrated as default. The ligand conformation with the highest XP Glide 
score was selected (26).
RESULTS AND DISCUSSION
Chemistry
The reaction of piperazine with various substituted sulfonyl chlorides, 2-chlorophenyl-
sulfonyl chloride, 3-chlorophenylsulfonyl chloride, 4-chlorophenylsulfonyl chloride, 
 2-tosylsulfonyl chloride, 3-tosylsulfonyl chloride, 4-tosylsulfonyl chloride, 3,5-difluoro-
phenylsulfonyl chloride, 2,6-difluorophenylsulfonyl chloride or 4-(trifluoromethyl)phenyl-
sulfonyl chloride, in acetone, produced six novel compounds; 1a, 1b, 1c, 1e, 1g, and 1i, and 
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three previously synthesized compounds; 1d (27), 1f (27), and 1h (28) as shown in Scheme 
1. Sodium hydroxide was used as an acid scavenger. The reaction was achieved by the 
nucleophilic addition-elimination reaction. The lone pair of electrons of the piperazine 
nitrogen attacks the sulfonyl group of the substituted sulfonyl chloride leading to the 
remo val of chloride ions. Hydrochloric acid is formed in this reaction and was neutralized 
by sodium hydroxide (1a-e, 1g and 1h) or by triethylamine (1f and 1i). The reaction also 
took place on the second piperazine nitrogen utilizing another sulfonyl chloride molecule 
to create the targeted compounds 1a-i. Purification of the synthesized compounds was 
carried out using crystallization or column chromatography. It was found that the reaction 
yield was greatly enhanced when acetone and sodium hydroxide were used (1a-e, 1g and 
1h) instead of dichloromethane and triethylamine (1f and 1i). Compound 1a was estab-
lished to show a maximum yield of 76.0 %.
Structures of compounds 1a-i were confirmed by IR, 1H, 13C NMR and MS spectra. All 
spectral data are given in Table I. Piperazine hydrogen atoms in 1H NMR spectra appeared 
as singlets at δ 2.99, 3.02, 3.05, 3.08, 3.11, 3.15, 3.20, 3.24, and 3.27 ppm with a total number 
of eight hydrogens. Aromatic protons appeared at δ 7.19–7.90 ppm, and the coupling of the 
peaks was dependent on the type of the aromatic substitution whether ortho, meta or para. 
Methyl protons of compounds 1d-f appeared as singlets at δ 2.42–2.57 ppm with a total 
number of six hydrogens. Piperazine carbon atoms in 13C NMR spectra were located at δ 
40.5–45.8 ppm and gave the count of four carbons. Phenyl carbons appeared in the aro-
matic region δ 109.8–160.3 ppm and gave the appropriate atom count of twelve carbons. 
Methyl carbons of compounds 1d-f were located at δ 20.7–21.6 ppm with a count of two 
carbons.
In addition, aliphatic and aromatic C-H stretching vibration bands appeared in IR 
spectra at 2936–2853 and 3098–3003 cm–1, resp. Aromatic C=C stretching vibration bands 
were located at 1614–1412 cm–1. Furthermore, the presence of the sulfonyl functional group 
was indicated by the appearance of strong stretching vibration bands at 1306–1159 cm–1.
The chemical structure of the compounds was also supported by high-resolution mass 
spectroscopy (HR-MS). Molecular ion peaks corresponding to the expected molecular 
 formulas were obtained. m/z data and the expected relative molecular masses (Mr) are 
given in Table I, together with other spectral and physicochemical data. IR and NMR 
 spectra are presented in Supplementary Material.







1a, R = 2-Cl
1b, R = 3-Cl
1c, R = 4-Cl
1d, R = 2-CH3
1e, R = 3-CH3
1f, R = 4-CH3
1g, R = 3,5-di F
1h, R = 2,6-di F
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In vitro DPP-IV inhibition bioassay
The results of in vitro DPP-IV inhibition bioassay are shown in Table II. Some of the 
compounds have noticeable inhibitory activity against DPP-IV at a concentration of 100 
µmol L–1. The best results were found for compounds 1a, 1c, 1h and 1i which nearly had 
one-third of the inhibitory activity of the used positive control, sitagliptin, at 100 µmol L–1.
It was noticed that ortho- and para-substituted compounds (1a, 1c, 1d, 1f, 1h and 1i) 
either with electron-withdrawing (EWG) or electron-donating group (EDG) enhance the 
activity more than the meta substituted ones (1b, 1e and 1g). On the other hand, the pres-
ence of two fluoro moieties at ortho-positions (1h) enhanced the activity more than meta 
groups (1g). Generally, the presence of EWG such as Cl (1a-c) improved the activity of the 
compounds more than EDG such as CH3 (1d-f) at the same positions.
Computational research
In order to investigate the binding modes of the co-crystallized ligand (N7F), sita-
gliptin, and the synthesized compounds 1a-i in the 4A5S binding site, we recruited indu-
ced-fit docking (IFD) against 4A5S. The IFD software investigates the conformation 
 changes in proteins specifically; ligands are docked to a protein’s binding domain imple-
menting Glide docking (26, 29, 30) and the highest ligand poses are minimized along with 
protein binding domain recruiting the Prime module (26). Consequently, a redocking 
 protocol is performed against the relaxed protein.
IFD studies demonstrate that N7F, sitagliptin, and 1a-i occupy the 4A5S binding 
 domain (Fig. 2a) and form H-bonding with the backbones of R125, E205, E206, F357, K554, 
W629, Y631, Y662, and R669 (Table III, Fig. 3 and Figs. S1-S2). Indeed, the docked pose of 1a 
superposes that of sitagliptin conformation (Fig. 2b). Furthermore, the significance of these 
residues has been detailed in experimental (25) and computational (22, 23) studies.
It has been pointed out that compounds 1a-i show equivalent binding affinity pre-
sented by docking scores (Table III) against 4A5S. A difference in 1.73 kcal mol–1 between 
Table II. Preliminary results for in vitro inhibition of DPP-IV by compounds 1a-i











a 100 mmol L–1. Mean of duplicate repetitions.
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the highest and the lowest binding energy within the 1a-i series implies that compounds 
1a-i demonstrate comparable binding energy towards the DPP-IV binding site. Moreover, 
the difference in the binding scores of N7F and sitagliptin to those of 1a-i infers that  further 
optimization of this scaffold is needed to obtain active DPP-IV inhibitors.
In order to assess the execution of the IFD program, we compared the induced-fit 
docked pose of N7F in DPP-IV (PDB ID: 4A5S) (25) to its native conformation in the crystal 
structure. Fig. 4 shows the superposition of the IFD-produced N7F pose and native geo-
metry in 4A5S. The relative mean square deviation (RMSD) for heavy atoms of N7F between 
Table III. IFD scores against DPP-IV enzyme and H-bond interactions
Compd. Docking score (kcal mol–1) H-bond
1a –6.85 Y631, R669
1b –6.51 R669
1c –7.08 R125, R669
1d –6.79 R669
1e –6.71 R125, K554
1f –8.00 R669, N710
1g –6.09 S630, R669, N710
1h –6.27 R125, K554, W629
1i –7.61 R125, K554, W629
N7F –9.26 E205, E206, Y631
Sitagliptin –10.22 E205, E206, S209, F357, Y547, Y662 
E – GLU, F – PHE, IFD – induced-fit docking, K – LYS, N – ASN, R – ARG, S – SER, W – TRP, Y – TYR
Fig. 2. a) The binding site 4A5S accommodates IF-docked poses of N7F, sitagliptin, and 1a-i. b) Super-
posing of IF-docked pose of sitagliptin (orange) and 1a (green). Some of the key binding residues are 
declared and H atoms are hidden for clarification. Picture visualized by PYMOL. E – GLU, F – PHE, 
H – HIS, K – LYS, N – ASN, R – ARG, S – SER, V – VAL, W – TRP, Y – TYR.
a)                                                                            b)
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Fig. 4. a) The superposition of N7F IF docked pose and its native conformation in 4A5S. The native 
structure is shown in gold and the docked pose in pink. b) 2D structure of N7F. C atoms are repre-
sented in grey, N in blue, and O in red color. The picture is extracted by PYMOL.
Fig. 3. Ligand/DPP-IV complex of: a) 1h and b) 1i. The hydrophobic lining is colored in green, the 
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IFD-generated docked geometry and native pose was 0.7167 Å. Results announce that IFD 
docking is capable to generate the native pose in the crystal structure and it is able to anti-
cipate the ligand-binding geometry.
The in vitro biological data demonstrate that derivatives tailored on o- or p-positions 
illustrated with 1a, 1c, 1h, and 1i exerted the highest biological activity which, in fact, is 
comparable to each other regarding DPP-IV inhibition. Results suggest that the binding 
site can properly accommodate small (F) (1h) or large (Cl or CF3) (1a, 1c, and 1i) sized sub-
stituent in o- or p-position.
Contrarily, analogues functionalized with –CH3 in o- or p-position (1d and 1f) exhibi-
ted lower activity reflecting that EWG displays better activity than that of EDG, and may 
suggest that the methyl group impedes the proper orientation of the core structure in the 
binding cleft. Although -Cl and -CH3 are bioisosteres to each other, there is a conforma-
tional restriction which orientates the analogue perfectly in the binding site. Furthermore, 
the difference in activity between 1f and 1i supports that conformational impedance influ-
ences ligand/DPP-IV complex formation.
However, the activity of 1g infers that m-substitution is not favored: the activity of 1b 
and 1e provides further evidence that m-attachment is disfavored.
CONCLUSIONS
In conclusion, successful synthesis and full characterization of six novel and three 
known piperazine sulfonamides were conducted. It was established that the compounds 
show prospective inhibitory activity against DPP-IV enzyme, especially compounds 
1,4-bis(2-chlorophenylsulfonyl) piperazine (1a), 1,4-bis(4-chlorophenylsulfonyl) piperazine 
(1c), 1,4-bis(2,6-difluorophenylsulfonyl) piperazine (1h) and 1,4-bis(4-(trifluoromethyl)phe-
nylsulfonyl) piperazine (1i). In general, it was noticed that the presence of EWG improves 
the activity of the compounds more than EDG at the same positions. Moreover, ortho- and 
para-substitution enhance the inhibitory activity, whereas meta-attachment is disfavored.
Abbreviations, acronyms, symbols. – DPP-IV – dipeptidyl peptidase-IV, EDG – electron-donating 
group, EWG – electron-withdrawing, GIP – glucose-dependent insulinotropic polypeptide, GLP-1 – 
glucagon-like peptide, IFD – induced-fit docking, PDB – protein data bank, RMSD – relative mean 
square deviation.
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